Please stop getting your news from fake memes and then repeating those lies
CLAIM: President Joe Biden raised insulin prices after former President Donald Trump lowered them.
AP’S ASSESSMENT: Misleading. The president doesn’t set the price of drugs. The Biden administration repealed a narrow, Trump-era regulation that sought to lower the cost of insulin at federally funded health centers. The regulation was never implemented and experts say its impact was expected to be limited.
THE FACTS: Biden called for capping the cost of insulin during his State of the Union address.
Referring to a 13-year-old with diabetes who was present for the remarks, Biden
said: “For Joshua, and for the 200,000 other young people with Type 1 diabetes, let’s cap the cost of insulin at $35 a month so everyone can afford it.”
But online, his words were met with misleading claims suggesting the president was himself responsible for the current high costs of the drug.
Republican Rep. Lauren Boebert tweeted, “Joe Biden is the one who raised the price of insulin after Trump lowered it.”
“Biden LITERALLY CREATED THE INSULIN COST INCREASE,” one conservative personality said in a tweet that garnered more than 30,000 likes.
In reality, insulin costs have been increasing for years and health policy experts say presidents don’t have the power to simply set drug prices.
Stacie Dusetzina, an associate professor of health policy at Vanderbilt University, said that prices are set by drug makers and market forces. The government doesn’t typically negotiate prices for most Americans, Dusetzina added in an email to The Associated Press.
Boebert’s office didn’t respond to a request for more information on her claim, but experts say such assertions are likely referring to a narrow rule that the Biden administration
repealed last year.
That rule pertained specifically to federally funded health centers, which
provide services to underserved communities. Finalized in late 2020, the rule aimed to ensure that such health centers were passing along discounted rates of insulin and injectable epinephrine, used for
allergic reactions. It was not fully implemented before it was rescinded and experts said any impact was expected to be minimal.
The Biden administration argued that the rule would have created additional administrative work and resulted in reduced resources at such centers.
“The rule was not likely to have had a substantial impact on very many patients and it was expected to impose substantial administrative burden on these federal health centers,” said Juliette Cubanski, deputy director for the Program on Medicare Policy at Kaiser Family Foundation.
Cubanski said it “wouldn’t have done anything to lower insulin prices across the board for the vast majority of insulin users.”
Rachel Sachs, a law professor at Washington University in St. Louis with expertise on health law, agreed. She also said in an email that such centers “are already required to provide products and services at low or no cost to most of their patients.”
Dusetzina likewise noted that those not treated at federally funded health centers would not have benefitted from the rule; 1 in 11 people are
estimated to be treated at such centers.
Separately, the Trump administration implemented a program in which some Medicare Part D and Medicare Advantage plans voluntarily set the maximum copay for insulin at $35 per month. However, not all insulin products are
necessarily covered by the plans that participate. It also does not affect costs for people who are uninsured or have other coverage.
That program remains in place, and Cubanski pointed out that the Biden administration supported expanding that initiative. A provision under the
idling Build Back Better Act would have applied it to private insurers, for example.
Biden called for capping the cost of insulin during his State of the Union address. Referring to a 13-year-old with diabetes who was present for the remarks, Biden said: “For Joshua, and for the 200,000 other young people with Type 1 diabetes, let’s cap the cost of insulin at $35 a month so everyone
apnews.com